Alcon launches the first DSLT device in thee US; the FDA approves an expanded label for Astellas Pharma's geographic atrophy drug Izervay; and New World Medical received FDA clearance for the VIA360 Surgical System. 

Learn more about your ad choices. Visit megaphone.fm/adchoices

The AAO responds to a proposal by the NIH to limit indirect funding for research projects; Lumenis launches a new device to address lower lid laxity and impaired blinking; and AI Optics receives FDA clearance for a handheld retinal imaging system.

Learn more about your ad choices. Visit megaphone.fm/adchoices

The FDA approves a label expansion for Genentech’s Susvimo implant; Iantrek completes the first commercial cases of its C.Rex micro-interventional system; and there are several executive leadership announcements made in ophthalmology.

Learn more about your ad choices. Visit megaphone.fm/adchoices

The world’s first and only pattern scanning laser indirect ophthalmoscope is approved in the US and Europe; the European Commission approves a biosimilar to Eylea; and we review several clinical updates in the development of ophthalmic drugs.

Learn more about your ad choices. Visit megaphone.fm/adchoices

Zeiss receives a major approval for its new excimer laser;

Bausch + Lomb makes two deals to bolster its pipeline in glaucoma and geographic atrophy; and Rayner announces the full European launch of its RayOne Galaxy IOLs.

Learn more about your ad choices. Visit megaphone.fm/adchoices

Leaders from Cure Blindness Project discuss efforts to restore vision and prevent avoidable blindness in underserved communities around the world.

Learn more about your ad choices. Visit megaphone.fm/adchoices

Glaukos submits a new drug application to the FDA for its next-generation cross-linking therapy; Regeneron releases phase 3 results for Eylea HD for RVO; and Regeneron acquires a clinical stage biotech making ocular delivery technology for retinal disorders.

Learn more about your ad choices. Visit megaphone.fm/adchoices

In today’s episode, we review the top stories from the second half of 2024. The last six months saw the launch of first-of-its-kind IOLS; the clinical advancement of gene therapies for rare diseases; the FDA approval of a device to treat patients with dry AMD; and introduction of novel OCTA technology.

Learn more about your ad choices. Visit megaphone.fm/adchoices

In today’s broadcast, we look back at the top stories from the first half of 2024. There were several advancements made during the first six months., including the approval of an excimer laser platform; the global adoption of sustained-released anti-VEGF treatments for retinal diseases; the rollout of autonomous AI screening technology; and a total solar eclipse.

Learn more about your ad choices. Visit megaphone.fm/adchoices

Bausch + Lomb makes an acquisition to expand its glaucoma offerings; Roche gets a major approval in Europe for Vabysmo; and EssilorLuxottica buys a maker of noninvasive ophthalmic medical devices.

Learn more about your ad choices. Visit megaphone.fm/adchoices